Zydus recalls single lot of blood thinner warfarin

Zydus Pharmaceuticals is recalling a single lot of the drug warfarin after receiving a complaint that some of the tablets are too large.

Zydus says it is recalling all of warfarin lot MM5767 with an expiration date of June 2014. The company says it has not received any reports of patient injury or harm.

Warfarin is a blood thinner widely used to prevent blood clots in patients with irregular heartbeats, or a history of heart attack. An overdose of could cause excessive bleeding and potentially be fatal.

The drugmaker says the affected products were distributed to wholesalers, retailers and mail order providers nationwide between November and December 2012.

Anyone with the product should stop selling or using it immediately and call 1-800-967-5952 to arrange its return to the manufacturer.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New blood thinner beats older drug for vein clots

Feb 20, 2013

(HealthDay)—People who need to take a blood thinner because they've had a clot in the deep veins of their legs appear to do better with the new drug Pradaxa (dibigatran) than with the older drug warfarin, ...

Kcentra approved to stop severe bleeding in heart patients

Apr 30, 2013

(HealthDay)—Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and ...

Recommended for you

Determine patient preferences by means of conjoint analysis

11 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments